Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2023

Efecto de Upadacitinib en la actividad de la enfermedad, el dolor, la fatiga, la función, la calidad de vida relacionada con la salud y la productividad laboral en la espondilitis anquilosante refractaria al tratamiento con fármacos biológicos

Rheumatol Ther 2023; 10:679–91 doi 10.1007/s40744-023-00536-2

Song IH,

Ganz F,

Stigler J,

Deodhar A

Upadacitinib significantly improved patient-reported outcomes in AxSpA patients with bDMARD-IR after 14 Weeks of treatment. There were notable improvements in disease activity, pain, fatigue, function, HRQoL, and work productivity.

Keywords:

Efecto de golimumab intravenoso en la fatiga y la relación con la respuesta clínica en adultos con espondilitis anquilosante activa en el estudio de fase 3 estudio de fase 3 GO-ALIVE

Rheumatol Ther. 2023;10(4):983–999 doi 10.1007/s40744-023-00556-y

Deodhar A,

Shiff NJ,

Gong C,

Chan EK,

Hsia EC,

Lo KH,

Akawung A,

Kim L,

Xu S,

Reveille JD

Administration of IV-golimumab 2 mg/kg improves fatigue symptoms in axial spondylitis in a 52 Week study. At Week 16 of treatment, improvements in ASAS, ASDAS, BASDAI and SF-36 scores were observed at week 16 of treatment.

Keywords:

May 2023

Efficacy and Safety of Upadacitinib in Patients with Active Psoriatic Arthritis and Axial Involvement: Results From Two Phase 3 Studies

Arthritis Res Ther. 2023;25(1):56 doi 10.1186/s13075-023-03027-5

Ranza R,

Gao T,

Kato k,

Song IH,

Granz F,

Deodhar A

Evidence from two phase 3 RCTs showed that patients with PsA and axial involvement had greater responses when treated with a once-daily oral dose of 15 mg upadacitinib versus placebo, and a similar or greater response versus adalimumab. Safety results were comparable between patients with or without axial involvement.

Keywords:

April 2023

Guselkumab, un inhibidor selectivo de la subunidad p19 de la Interleukina-23, resuelve la dactilitis en pacientes con artritis psoriásica activa: resultados agrupados a lo largo de 52 semanas desde dos estudios de fase 3

ACR Open Rheumatol. 2023;5(4):227–240 doi 10.1002/acr2.11537

Shawi M,

Xu XL,

Sheng S,

Xu S,

Ritchlin CT,

Rahman P,

Mease PJ

Post hoc analysis of guselkumab, Phase 3 DISCOVER-1 and -2 studies finds that 75% of guselkumab-randomised patients have complete resolution of dactylitis through one year.

Keywords:

Eficacia y Seguridad Multidominios de Guselkumab a lo largo de 1 Año en Pacientes con Artritis Psoriásica Activa con y sin Exposición a Inhibidores del Factor de Necrosis Tumoral: Análisis del Ensayo de Fase 3, Aleatorizado, Controlado con Placebo DISCOVER-1

ACR Open Rheumatol. 2023 doi: 10.1002/acr2.11523

Xu XL,

Shawi M,

Jiang Y,

Sheng S,

Helliwell PS

TNF inhibitors (TNFi) are one main mode of therapy in patients with PsA who fail to respond to csDMARDs. However, they have a primary treatment failure rate of 40% and only a modest target of ≥20% ACR20 response. The objective of this study was to evaluate efficacy and safety of guselkumab, interleukin-23 inhibitor in the DISCOVER-1 study with active PsA patients by prior use of TNFi.

Keywords:

March 2023

Perfil de seguridad de upadacitinib en 15 000 pacientes-año con artritis reumatoide, artritis psoriásica, espondilitis anquilosante y dermatitis atópica

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Nash P,

Liu J,

Palac H,

Shaw T,

Mease PJ,

Guttman-Yassky E

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

February 2023

Eficacia y Seguridad de Bimekizumab en las Espondiloartritis Axiales: Resultados de Dos Ensayos Paralelos de Fase 3 Aleatorizados y Controlados

Ann Rheum Dis. 2023 Jan 17 doi: 10.1136/ard-2022-223595

Vaux T,

Bimekizumab may therefore offer patients with axSpA an effective treatment option with a novel mode of action.

Keywords:

January 2023

Seguridad y Eficacia de Bimekizumab en Pacientes con Espondilitis Anquilosante Activa: resultados de tres años de un estudio de fase IIb aleatorizado controlado y su estudio de extensión abierto

Arthritis Rheumatol. 2022;74:1943–58

Molto A,

Vaux T,

In this open-label extension study of BE AGILE, the safety profile of bimekizumab was found to be consistent with previously demonstrated findings, and no new safety signals were identified. The objective was to assess the long-term safety, tolerability, and efficacy of bimekizumab in patients with active AS.

Keywords:

October 2022

Certolizumab Pegol Efficacy in Patients with Non-Radiographic Axial Spondyloarthritis Stratified by Baseline MRI and C-Reactive Protein Status: An Analysis From the C-axSp And Study

ACR Open Rheumatol. 2022 doi: 10.1002/acr2.11469

Hall S,

Bauer L,

Kumke T,

Kim M,

de Peyrecave N,

Deodhar A

The results of this analysis indicated that certolizumab pegol (CZP) treatment benefits patients with nr-axSpA across all the MRI/CRP subgroups studied. To reach this conclusion, this study evaluated clinical responses to CZP in patients with nr-axSpA stratified by baseline MRI/CRP status.

September 2022

Efficacy and Safety of Ixekizumab Treatment in Patients with Axial Spondyloarthritis: 2-year Results from COAST

RMD Open. 2022 doi: 10.1136/rmdopen-2021-002165

Braun J,

Kiltz U,

Bolce R,

Lin CY,

This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.